The themes Twist Bioscience is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Twist Bioscience Corporation’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$122.71-7.1%Nov 11 close
The latest quarter (ended September 30, 2026) is from Twist Bioscience’s earnings press release of November 12, 2026. It will be replaced by the official annual report (10-K) once Twist Bioscience files it.
Company outlook: revenue of $130M to $132M for Fiscal Q1 2027 — up 26.3% on a year earlier
Grade C-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 29 quarters of Twist Bioscience Corporation’s grade history. The other 27 go back to December 2019.